stockrow
Friday 6 November 2026
Export NVS’s income statement to Excel — free account
Novartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
162.65
0.72
+0.44%
Follow NVS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
19.15 | 21.76 | 23.53 | 27.15 |
P/S ratio |
4.72 | 5.15 | 5.27 | 4.71 | |
P/FCF ratio |
17.34 | 18.08 | 19.67 | 19.11 | |
P/Operating CF |
118.08 | 79.33 | 50.76 | 49.12 | |
P/B ratio |
5.74 | 7.49 | 7.12 | 7.20 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.10 | 5.83 | 5.96 | 5.36 | |
EV/EBITDA |
12.62 | 14.65 | 14.99 | 13.90 | |
EV/Operating CF |
15.11 | 17.19 | 18.37 | 17.76 | |
EV/FCF |
18.76 | 20.44 | 22.27 | 21.75 | |
Quick Ratio |
0.76 | 0.53 | 0.55 | 0.58 | |
Current Ratio |
1.12 | 0.85 | 0.86 | 0.88 | |
Net Debt/EBITDA |
4.26 | 7.00 | 6.40 | 6.94 | |
Debt/Assets |
30.23% | 38.02% | 38.58% | 39.56% | |
Debt/Equity |
0.72 | 1.16 | 1.12 | 1.23 | |
Asset Turnover |
0.53 | 0.52 | 0.50 | 0.51 | |
Operating CF/Net income |
0.94 | 1.16 | 1.80 | 4.58 | |
Capex/Depreciation |
(0.59) | (0.68) | (0.50) | (0.21) | |
Interest Coverage |
11.89 | 12.35 | 10.28 | 3.94 | |
Research and Development Expense of Revenue |
22.82% | 20.26% | 19.04% | 34.27% | |
Selling, General and Administrative Expense of Revenue |
24.82% | 23.22% | 21.68% | 20.51% | |
Intangible Assets out of Total Assets |
0.50 | 0.57 | 0.56 | 0.57 | |
Share Based Compensation of Revenue |
2.16% | 2.24% | 1.79% | 1.78% | |
Graham Net Nets |
(0.13) | (0.18) | (0.18) | (0.19) | |
Graham Number |
62.36 | 56.75 | 57.44 | 48.38 | |
Earnings Yield |
5.22% | 4.60% | 4.25% | 3.68% | |
Free Cash Flow Yield |
5.77% | 5.53% | 5.08% | 5.23% | |
Revenue per Share |
7.15 | 7.08 | 7.85 | 7.93 | |
Operating CF per Share |
1.17 | 1.93 | 3.09 | 2.90 | |
Capex per Share |
(0.47) | (0.43) | (0.37) | (0.39) | |
Free Cash Flow per Share |
0.70 | 1.49 | 2.72 | 2.51 | |
Cash per Share |
5.98 | 3.65 | 4.04 | 4.73 | |
Shareholders Equity per Share |
24.01 | 20.39 | 22.02 | 19.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
24.01 | 20.39 | 22.02 | 19.81 | |
Free Cash Flow |
1,360.00 | 2,850.00 | 5,174.00 | 4,761.00 | |
Working Capital |
3,182.00 | (4,767.00) | (4,397.00) | (3,778.00) | |
Capital Expenditures |
(904.00) | (826.00) | (708.00) | (742.00) | |
Net Current Asset Value |
(33,940.00) | (52,998.00) | (52,736.00) | (50,838.00) | |
EV/EBIT |
16.40 | 19.15 | 19.76 | 21.30 | |
Capex to Sales |
0.07 | 0.06 | 0.05 | 0.05 | |
Price to Operating Income |
15.15 | 16.94 | 17.46 | 18.71 | |
| Other line items | |||||
Average Receivables |
8,349.00 | 9,163.50 | 9,515.00 | 9,473.50 | |
Average Payables |
4,514.00 | 4,291.50 | 4,382.00 | 4,399.00 | |
Average Inventory |
5,996.00 | 6,057.50 | 6,263.50 | 6,262.50 | |
Average Assets |
106,597.50 | 109,236.50 | 113,214.00 | 112,219.00 | |
Average Common Equity |
45,337.50 | 38,689.50 | 42,000.00 | 41,158.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026